Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Identifieur interne : 000013 ( PubMed/Curation ); précédent : 000012; suivant : 000014Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Auteurs : Hiroko Ito [Japon] ; Hidekazu Nishimura [Japon] ; Tomoko Kisu [Japon] ; Haruhisa Hagiwara [Japon] ; Oshi Watanabe [Japon] ; Francois Marie Ngako Kadji [Japon] ; Ko Sato [Japon] ; Suguru Omiya [Japon] ; Emi Takashita [Japon] ; Eri Nobusawa [Japon]Source :
- PloS one [ 1932-6203 ] ; 2020.
Abstract
Antibodies against influenza virus neuraminidase (NA) protein prevent releasing of the virus from host cells and spreading of infection foci and are considered the 'second line of defence' against influenza. Haemagglutinin inhibition antibody-low responders (HI-LRs) are present among influenza split vaccine recipients. The NA inhibition (NAI) antibody response in vaccinees is worth exploring, especially those in the HI-LRs population. We collected pre- and post-vaccination sera from 61 recipients of an inactivated, monovalent, split vaccine against A/H1N1pdm09 and acute and convalescent sera from 49 unvaccinated patients naturally infected with the A/H1N1pdm09 virus during the 2009 influenza pandemic. All samples were subjected to haemagglutinin inhibition (HI), NAI and neutralisation assays. Most paired sera from naturally infected patients exhibited marked elevation in the NAI activity, and seroconversion rates (SCR) among HI-LRs and HI-responders (HI-Rs) were 60% and 87%, respectively; however, those from vaccinees displayed low increase in the NAI activity, and the SCR among HI-LRs and HI-Rs were 0% and 12%, respectively. In both HI-LRs and HI-Rs, vaccination with the inactivated, monovalent, split vaccine failed to elicit the NAI activity efficiently in the sera of the naive population, compared with the natural infection. Hence, the improvement of influenza vaccines is warranted to elicit not only HI but also NAI antibodies.
DOI: 10.1371/journal.pone.0233001
PubMed: 32401814
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000013
Links to Exploration step
pubmed:32401814Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.</title><author><name sortKey="Ito, Hiroko" sort="Ito, Hiroko" uniqKey="Ito H" first="Hiroko" last="Ito">Hiroko Ito</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Nishimura, Hidekazu" sort="Nishimura, Hidekazu" uniqKey="Nishimura H" first="Hidekazu" last="Nishimura">Hidekazu Nishimura</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Kisu, Tomoko" sort="Kisu, Tomoko" uniqKey="Kisu T" first="Tomoko" last="Kisu">Tomoko Kisu</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Hagiwara, Haruhisa" sort="Hagiwara, Haruhisa" uniqKey="Hagiwara H" first="Haruhisa" last="Hagiwara">Haruhisa Hagiwara</name><affiliation wicri:level="1"><nlm:affiliation>Hagiwara Clinic, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Hagiwara Clinic, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Watanabe, Oshi" sort="Watanabe, Oshi" uniqKey="Watanabe O" first="Oshi" last="Watanabe">Oshi Watanabe</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Kadji, Francois Marie Ngako" sort="Kadji, Francois Marie Ngako" uniqKey="Kadji F" first="Francois Marie Ngako" last="Kadji">Francois Marie Ngako Kadji</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Sato, Ko" sort="Sato, Ko" uniqKey="Sato K" first="Ko" last="Sato">Ko Sato</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Omiya, Suguru" sort="Omiya, Suguru" uniqKey="Omiya S" first="Suguru" last="Omiya">Suguru Omiya</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Takashita, Emi" sort="Takashita, Emi" uniqKey="Takashita E" first="Emi" last="Takashita">Emi Takashita</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Nobusawa, Eri" sort="Nobusawa, Eri" uniqKey="Nobusawa E" first="Eri" last="Nobusawa">Eri Nobusawa</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32401814</idno><idno type="pmid">32401814</idno><idno type="doi">10.1371/journal.pone.0233001</idno><idno type="wicri:Area/PubMed/Corpus">000013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000013</idno><idno type="wicri:Area/PubMed/Curation">000013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000013</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.</title><author><name sortKey="Ito, Hiroko" sort="Ito, Hiroko" uniqKey="Ito H" first="Hiroko" last="Ito">Hiroko Ito</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Nishimura, Hidekazu" sort="Nishimura, Hidekazu" uniqKey="Nishimura H" first="Hidekazu" last="Nishimura">Hidekazu Nishimura</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Kisu, Tomoko" sort="Kisu, Tomoko" uniqKey="Kisu T" first="Tomoko" last="Kisu">Tomoko Kisu</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Hagiwara, Haruhisa" sort="Hagiwara, Haruhisa" uniqKey="Hagiwara H" first="Haruhisa" last="Hagiwara">Haruhisa Hagiwara</name><affiliation wicri:level="1"><nlm:affiliation>Hagiwara Clinic, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Hagiwara Clinic, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Watanabe, Oshi" sort="Watanabe, Oshi" uniqKey="Watanabe O" first="Oshi" last="Watanabe">Oshi Watanabe</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Kadji, Francois Marie Ngako" sort="Kadji, Francois Marie Ngako" uniqKey="Kadji F" first="Francois Marie Ngako" last="Kadji">Francois Marie Ngako Kadji</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Sato, Ko" sort="Sato, Ko" uniqKey="Sato K" first="Ko" last="Sato">Ko Sato</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Omiya, Suguru" sort="Omiya, Suguru" uniqKey="Omiya S" first="Suguru" last="Omiya">Suguru Omiya</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai</wicri:regionArea></affiliation></author><author><name sortKey="Takashita, Emi" sort="Takashita, Emi" uniqKey="Takashita E" first="Emi" last="Takashita">Emi Takashita</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Nobusawa, Eri" sort="Nobusawa, Eri" uniqKey="Nobusawa E" first="Eri" last="Nobusawa">Eri Nobusawa</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo</wicri:regionArea></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antibodies against influenza virus neuraminidase (NA) protein prevent releasing of the virus from host cells and spreading of infection foci and are considered the 'second line of defence' against influenza. Haemagglutinin inhibition antibody-low responders (HI-LRs) are present among influenza split vaccine recipients. The NA inhibition (NAI) antibody response in vaccinees is worth exploring, especially those in the HI-LRs population. We collected pre- and post-vaccination sera from 61 recipients of an inactivated, monovalent, split vaccine against A/H1N1pdm09 and acute and convalescent sera from 49 unvaccinated patients naturally infected with the A/H1N1pdm09 virus during the 2009 influenza pandemic. All samples were subjected to haemagglutinin inhibition (HI), NAI and neutralisation assays. Most paired sera from naturally infected patients exhibited marked elevation in the NAI activity, and seroconversion rates (SCR) among HI-LRs and HI-responders (HI-Rs) were 60% and 87%, respectively; however, those from vaccinees displayed low increase in the NAI activity, and the SCR among HI-LRs and HI-Rs were 0% and 12%, respectively. In both HI-LRs and HI-Rs, vaccination with the inactivated, monovalent, split vaccine failed to elicit the NAI activity efficiently in the sera of the naive population, compared with the natural infection. Hence, the improvement of influenza vaccines is warranted to elicit not only HI but also NAI antibodies.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">32401814</PMID><DateRevised><Year>2020</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.</ArticleTitle><Pagination><MedlinePgn>e0233001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0233001</ELocationID><Abstract><AbstractText>Antibodies against influenza virus neuraminidase (NA) protein prevent releasing of the virus from host cells and spreading of infection foci and are considered the 'second line of defence' against influenza. Haemagglutinin inhibition antibody-low responders (HI-LRs) are present among influenza split vaccine recipients. The NA inhibition (NAI) antibody response in vaccinees is worth exploring, especially those in the HI-LRs population. We collected pre- and post-vaccination sera from 61 recipients of an inactivated, monovalent, split vaccine against A/H1N1pdm09 and acute and convalescent sera from 49 unvaccinated patients naturally infected with the A/H1N1pdm09 virus during the 2009 influenza pandemic. All samples were subjected to haemagglutinin inhibition (HI), NAI and neutralisation assays. Most paired sera from naturally infected patients exhibited marked elevation in the NAI activity, and seroconversion rates (SCR) among HI-LRs and HI-responders (HI-Rs) were 60% and 87%, respectively; however, those from vaccinees displayed low increase in the NAI activity, and the SCR among HI-LRs and HI-Rs were 0% and 12%, respectively. In both HI-LRs and HI-Rs, vaccination with the inactivated, monovalent, split vaccine failed to elicit the NAI activity efficiently in the sera of the naive population, compared with the natural infection. Hence, the improvement of influenza vaccines is warranted to elicit not only HI but also NAI antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5681-7971</Identifier><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kisu</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiwara</LastName><ForeName>Haruhisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hagiwara Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Oshi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadji</LastName><ForeName>Francois Marie Ngako</ForeName><Initials>FMN</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Ko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omiya</LastName><ForeName>Suguru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Virus Research Center, National Hospital Organization Sendai Medical Center, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashita</LastName><ForeName>Emi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobusawa</LastName><ForeName>Eri</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32401814</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0233001</ArticleId><ArticleId IdType="pii">PONE-D-19-27759</ArticleId><ArticleId IdType="pmc">PMC7219752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 1998 May-Jun;16(9-10):1009-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9682352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1979 Dec;140(6):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">396336</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1971 Sep;107(3):730-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4999093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 1990 Dec 31;135(1-2):49-57</Citation><ArticleIdList><ArticleId IdType="pubmed">1703190</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Feb 25;28(9):2076-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20044052</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Mar 15;207(6):974-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23307936</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1995 Dec;13(18):1799-803</Citation><ArticleIdList><ArticleId IdType="pubmed">8701596</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2014 Jun 23;6(6):2465-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24960271</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Nov;78(22):12665-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15507653</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Sep;3(5):233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21462400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jun 25;459(7250):1122-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19516283</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2014 Dec 15;210:7-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25233882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Feb;89(3):1550-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25392225</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Aug 31;23(37):4598-609</Citation><ArticleIdList><ArticleId IdType="pubmed">15964668</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(10):e26335</Citation><ArticleIdList><ArticleId IdType="pubmed">22039464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Oct 15;212(8):1191-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25858957</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1972 Jun 22;286(25):1329-32</Citation><ArticleIdList><ArticleId IdType="pubmed">5027388</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2018 Apr 3;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29615508</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Jul 10;325(5937):197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">19465683</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2019;8(1):327-338</Citation><ArticleIdList><ArticleId IdType="pubmed">30866786</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jul 6;30(32):4762-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22643214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2018 Apr 5;173(2):417-429.e10</Citation><ArticleIdList><ArticleId IdType="pubmed">29625056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1973 Mar 24;1(7804):623-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4121842</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Dec 17;31(1):190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23107591</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2016 Apr 19;7(2):e00417-16</Citation><ArticleIdList><ArticleId IdType="pubmed">27094330</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2012 Jul;22(4):267-79</Citation><ArticleIdList><ArticleId IdType="pubmed">22438243</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Aug 12;10(8):e0135383</Citation><ArticleIdList><ArticleId IdType="pubmed">26267900</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000013 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000013 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32401814
|texte= Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32401814" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |